The New York University (NYU) School of Medicine JCOIN Research Center conducting a large multisite trial to compare the effectiveness of extended-release buprenorphine (Sublocade, XR-B) to extended-release naltrexone (XR-NTX). The trial will enroll individuals prior to release from jail and randomize to either medication option. The first dose of medication will be administered prior to release, with an additional 24 weeks of treatment received in the community.
Participating jails are located in Connecticut, Delaware, New Hampshire, New Jersey, and Oregon. The study will measure retention in treatment, and opioid and other substance use outcomes between the two medication conditions, as well as a sample of individuals who opt for other treatment options (“treatment as usual”).
Study Settings: Jails/Prisons, Treatment/Healthcare Settings
Study Locations: Connecticut, Delaware, New Hampshire, New Jersey, Oregon
- Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS) (2021)
- Peer Recovery Support Services Across the Continuum: In Community, Hospital, Corrections, and Treatment and Recovery Agency Settings – A Narrative Review (2022)
- The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study (2022)
- Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data (2023)
- Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non-Clinicians (2023)
PI: David Farabee, Elizabeth Waddell, Josh Lee, Lisa Marsch, Robert Schwartz, Sandra Springer
• Compare the effectiveness of XR-B vs XR-NTX on medication adherence (retention)
• Measure opioid and other substance use outcomes
• Compare study subjects to a treatment-as-usual sample
• Identify implications for the use of long-acting injectable MOUD in justice settings
Clinical Trial, MOUD Comparative Effectiveness